We found that MMP2 overexpression was significantly associated with shorter OS while MMP9 overexpression was related to shorter DFS and OS, indicating that MMP2 and MMP9 may serve as promising prognostic biomarkers for the treatment and management of BC patients. The gene discussed is MMP9; the disease is breast cancer.